
Accuray (ARAY) Stock Forecast & Price Target
Accuray (ARAY) Analyst Ratings
Bulls say
Accuray is expected to improve operating profitability by ~$25M annually through its transformation plan and has already recognized $10M in cost and margin improvements. Despite recent challenges, the company's technology, including its CyberKnife and TomoTherapy platforms, positions it as a leader in the radiation oncology space. However, the company's results have been impacted by geopolitical uncertainty, macroeconomic headwinds, and other factors which has led analysts to adopt a neutral stance.
Bears say
Accuray is a radiation oncology company, with its main system being CyberKnife. Unfortunately, the company has been impacted by geopolitical tensions and uncertainties, and has missed expectations on both adj. EBITDA and cost-cutting efforts. Though the company has a transformation plan underway, the lack of progress on commercial execution and profitability metrics, along with declining revenue, make it a risky investment at this time.
This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.
Accuray (ARAY) Analyst Forecast & Price Prediction
Start investing in Accuray (ARAY)
Order type
Buy in
Order amount
Est. shares
0 shares